Only two pipeline agents in the cardiovascular space are expected to reach blockbuster status (with sales over $1 billion) by 2024.
13 March 2019 Comment
4 March 2019 News
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for blood pressure and heart...
28 February 2019 News
Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases.
25 February 2019 Digital Disruption
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy, from Akcea Therapeutics’ affiliate Ionis...
25 February 2019 News
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the...
13 February 2019 Analysis
February is National Heart Month in the UK and the US, which focuses on raising awareness of heart disease. Often caused by emotional distress, takotsubo cardiomyopathy is a rare heart...
11 February 2019 News
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%.
28 November 2018 News
Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in the treatment of liver diseases.
20 November 2018 Analysis
Heart disease is one of the leading causes of death in men and women, but women are commonly underrepresented in clinical trials. Could this negatively impact the treatment of female...
5 October 2018 Comment
The Asia-Pacific market for heart failure therapeutics was estimated at $733.7 million in 2017 and is projected to reach $1,435.9 million in 2024, increasing at a compound annual growth rate...